By Sriparna Roy (Reuters) -Privately held Stealth BioTherapeutics said on Thursday the U.S. Food and Drug Administration had declined to approve its therapy for an ultra-rare condition called Barth Syndrome,
Original Image Link
Source:www.msn.com
Original Image Link
Source:www.msn.com
Posted: 2025-05-29 10:05:01















